3-(2,4-二氟-苯氧基)-氮杂环丁烷 | 954225-05-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-(2,4-二氟-苯氧基)-氮杂环丁烷
• 英文名称: 3-(2,4-Difluorophenoxy)azetidine
• CAS: 954225-05-9
• 化学式: C₉H₉F₂NO
• 分子量: 185.17
• InChiKey: UTNJOKZHZHVICP-UHFFFAOYSA-N

物化性质

• 沸点：
  258.9±40.0 °C(Predicted)
• 密度：
  1.277±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

文献信息

• CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS
  申请人：Bregman Howard

  公开号：US20130131035A1

  公开（公告）日：2013-05-23

  The present invention provides compounds that are inhibitors of voltage-gated sodium channels (Nav), in particular Nav 1.7, and are therefore useful for the treatment of diseases treatable by inhibition of these channels, in particular, chronic pain disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了一种抑制电压门控钠通道（Nav）的化合物，特别是Nav 1.7，因此可用于治疗可通过抑制这些通道治疗的疾病，特别是慢性疼痛疾病。还提供了含有这种化合物的药物组合物以及制备这种化合物的方法。
• Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission
  申请人：Integrative Research Laboratories Sweden AB

  公开号：US10875829B1

  公开（公告）日：2020-12-29

  The disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula (I): (I) or an isotope labelled analog thereof, or a pharmaceutically acceptable salt thereof, wherein: each of R1, R2, R3, R6 and R7 represents H or F, R4 represents H or CH3 R5 represents H or C1-C4alkyl, wherein at least two of R1, R2, R3, R6 and R7 represent F, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

  本公开提供了一种药物组合物，其包含治疗有效量的式（I）化合物：(I) 或其同位素标记类似物，或其药学上可接受的盐，其中：R1、R2、R3、R6 和 R7 各代表 H 或 F，R4 代表 H 或 CH3，R5 代表 H 或 C1-C4 烷基，其中 R1、R2、R3、R6 和 R7 中至少有两个代表 F，与至少一种药学上可接受的载体、赋形剂和/或稀释剂一起。
• NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION
  申请人：Integrative Research Laboratories Sweden AB

  公开号：EP3541784A1

  公开（公告）日：2019-09-25
• Cyclic Ureas
  申请人：SIRONAX LTD

  公开号：US20210292305A1

  公开（公告）日：2021-09-23

  The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
• US9334269B2
  申请人：——

  公开号：US9334269B2

  公开（公告）日：2016-05-10